- Home
- BCAB vs MYO Comparison
BCAB vs MYO Comparison
Compare BCAB & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- MYO
- Stock Information
- Founded
- BCAB 2007
- MYO 2004
- Country
- BCAB United States
- MYO United States
- Employees
- BCAB N/A
- MYO N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- MYO Industrial Specialties
- Sector
- BCAB Health Care
- MYO Health Care
- Exchange
- BCAB Nasdaq
- MYO Nasdaq
- Market Cap
- BCAB 101.0M
- MYO 113.3M
- IPO Year
- BCAB 2020
- MYO 2017
- Fundamental
- Price
- BCAB $1.57
- MYO $5.10
- Analyst Decision
- BCAB Buy
- MYO Strong Buy
- Analyst Count
- BCAB 2
- MYO 4
- Target Price
- BCAB $5.00
- MYO $7.75
- AVG Volume (30 Days)
- BCAB 1.2M
- MYO 222.2K
- Earning Date
- BCAB 11-07-2024
- MYO 11-06-2024
- Dividend Yield
- BCAB N/A
- MYO N/A
- EPS Growth
- BCAB N/A
- MYO N/A
- EPS
- BCAB N/A
- MYO N/A
- Revenue
- BCAB $11,000,000.00
- MYO $25,239,125.00
- Revenue This Year
- BCAB N/A
- MYO $53.19
- Revenue Next Year
- BCAB N/A
- MYO $39.01
- P/E Ratio
- BCAB N/A
- MYO N/A
- Revenue Growth
- BCAB N/A
- MYO 36.23
- 52 Week Low
- BCAB $1.14
- MYO $2.51
- 52 Week High
- BCAB $4.02
- MYO $5.64
- Technical
- Relative Strength Index (RSI)
- BCAB 40.91
- MYO 66.20
- Support Level
- BCAB $1.33
- MYO $4.69
- Resistance Level
- BCAB $2.53
- MYO $5.15
- Average True Range (ATR)
- BCAB 0.26
- MYO 0.38
- MACD
- BCAB -0.07
- MYO 0.04
- Stochastic Oscillator
- BCAB 20.08
- MYO 83.87
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The Company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).